Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reactivation of chronic hepatitis B characterized by rise in ALT level \>5 times upper limit of normal along with HBV DNA level \>105 copies/ml (\~1.8x104 IU/ml) presenting as ACLF~* Acute hepatic insult~* Jaundice (bilirubin ≥5 mg/dL) and coagulopathy (INR\>1.5)~* Complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.~Exclusion Criteria:~* Superinfection with other viruses (Hepatitis E, A, D and C)~* Coexistent hepatocellular carcinoma (HCC)~* Portal vein thrombosis~* Coexistent renal impairment~* Pregnancy~* Co-infection with HIV infection or Patients received previous course of any antiviral~* Immunomodulator or cytotoxic/immunosuppressive therapy for chronic hepatitis or other illness within at least the preceding 12 month.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: NO_INTERVENTION): Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
- Tenofovir disoproxil fumarate (TDF) (Type: ACTIVE_COMPARATOR): Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF

Based on this trial design, predict the completion outcome and termination type (if applicable).